Jim Scibetta Named CEO of VectorY Therapeutics
Jim Scibetta appointed CEO at VectorY, leading ALS therapy VTx-002 into clinical trials by 2025.
VectorY Therapeutics has named Jim Scibetta as CEO, with founder Sander van Deventer transitioning to President of R&D. Scibetta, known for leading biotech innovations, will drive the clinical advancement of VTx-002, a promising vectorized antibody targeting TDP-43 for ALS, aiming to enter trials by 2025.
VectorY recently secured $138 million in Series A funding to develop its pipeline and has expanded to Boston. The company’s platform seeks to address neurodegenerative diseases by targeting underlying disease drivers, with VTx-002 positioned to preserve quality of life in ALS patients.
Reporting on the science, business and regulation shaping the pharmaceutical industry.
Más de Pharma News
Todos los artículos →
Medicus Pharma presenta al FDA el protocolo combinado de fase 2b/3 para Teverelix
Fresenius Kabi recibe una carta de advertencia de la FDA tras fallos en la investigación del procesamiento aséptico en la planta de Melrose Park
Discussion